Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

ASCO: Bevacizumab and standard adjuvant chemotherapy: no improvement in disease-free survival for early-stage colon cancer

Bookmark and Share

2009 ASCO Annual Meeting

29 May - 2 Jun 2009
Published: 17 Jun 2009
Views: 13186
Rating:
Save
Dr Norman Wolmark - Chairman Dept of Human Oncology, Allegheny General Hospital, US
ASCO press conference: Adding bevacizumab (avastin) to standard adjuvant chemotherapy does not improve disease-free survival for early-stage colon cancer

Related Videos

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy...
Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )
26 Jan 2023
HER-Vaxx is safe and provides clinical benefit over standard of care chemo for...
Dr Tanuj Chawla and Dr Giovanni Selvaggi
HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer ( Dr Tanuj Chawla and Dr Giovanni Selvaggi )
25 Jan 2023
Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and...
Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
25 Jan 2023
Kinetics of postop circulating cell-free DNA and impact on MRD detection rates...
Dr Stacey Cohen - Fred Hutchinson Cancer Center, Washington, USA
Kinetics of postop circulating cell-free DNA and impact on MRD detection rates in resected stage I-III colorectal cancer ( Dr Stacey Cohen - Fred Hutchinson Cancer Center, Washington, USA )
25 Jan 2023
OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not...
Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK
OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure ( Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK )
25 Jan 2023
NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful...
Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan
NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )
25 Jan 2023
Epidemiology, detection, and management of NAFLD: a Latin American perspective
Dr Nahum Mendez-Sanchez - National Autonomous University of Mexico, Mexico City...
Epidemiology, detection, and management of NAFLD: a Latin American perspective ( Dr Nahum Mendez-Sanchez - National Autonomous University of Mexico, Mexico City, Mexico )
20 Dec 2022
Genomic testing in biliary tract cancers
Dr Chiara Braconi - University of Glasgow, Glasgow, UK
Genomic testing in biliary tract cancers ( Dr Chiara Braconi - University of Glasgow, Glasgow, UK )
24 Oct 2022
Intraoperative Radiotherapy
Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal
Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )
25 Sep 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation